Meeting
2011 ASCO Annual Meeting
Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.
Authors
G. Lunardi
Sacro Cuore Don Calabria Hospital, Negrar, Italy
G. Lunardi , L. Del Mastro , C. Bighin , G. Bisagni , P. Driol , O. Garrone , S. Giraudi , P. Marroni , P. Piccioli , R. Ponzone , M. Porpiglia , M. Venturini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 29: 2011 (suppl; abstr 515)
Abstract #
515
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes.
First Author: Emily Anne Underwood
Poster
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
First Author: Elizabeth Joyce
Poster
2020 ASCO Virtual Scientific Program
Breast Cancer Index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial.
First Author: Gerrit-Jan Liefers
Poster
2018 ASCO Annual Meeting
Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer.
First Author: Jacqueline M Dempsey